Compare CLFD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | ASMB |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.2M | 499.8M |
| IPO Year | N/A | 2010 |
| Metric | CLFD | ASMB |
|---|---|---|
| Price | $31.27 | $27.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $43.50 | $43.40 |
| AVG Volume (30 Days) | ★ 123.7K | 111.3K |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,134,000.00 | $37,191,000.00 |
| Revenue This Year | $11.85 | $33.33 |
| Revenue Next Year | $23.09 | N/A |
| P/E Ratio | $69.36 | ★ N/A |
| Revenue Growth | 19.56 | ★ 31.30 |
| 52 Week Low | $23.78 | $7.75 |
| 52 Week High | $46.76 | $39.71 |
| Indicator | CLFD | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 38.89 |
| Support Level | $30.16 | $26.93 |
| Resistance Level | $32.72 | $28.59 |
| Average True Range (ATR) | 1.14 | 1.65 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 42.38 | 26.09 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.